A carregar...
Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling
Abemaciclib, a selective inhibitor of cyclin‐dependent kinases 4 and 6, is metabolized mainly by cytochrome P450 (CYP)3A4. Clinical studies were performed to assess the impact of strong inhibitor (clarithromycin) and inducer (rifampin) on the exposure of abemaciclib and active metabolites. A physiol...
Na minha lista:
| Publicado no: | J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7318171/ https://ncbi.nlm.nih.gov/pubmed/32080863 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1584 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|